MARKET

GNPX

GNPX

Genprex Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.490
-0.010
-0.29%
Pre Market: 3.340 -0.15 -4.30% 08:25 06/18 EDT
OPEN
3.530
PREV CLOSE
3.500
HIGH
3.580
LOW
3.450
VOLUME
2.70K
TURNOVER
--
52 WEEK HIGH
7.72
52 WEEK LOW
2.780
MARKET CAP
165.30M
P/E (TTM)
-7.4414
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 12m ago
Companies Like Genprex (NASDAQ:GNPX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 06/11 07:32
Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
Genprex's President and CEO will present at Noble Capital Markets’ Virtual Roadshow Series on Thursday, May 20 at 1 pm ET
Business Wire · 05/19 12:30
From BZ Small Cap Event: Wrap Technologies CEO Tom Smith Now Speaking Live
https://www.youtube.com/watch?v=Jrcq_ymSBt0
Benzinga · 05/14 15:36
Schedule For Benzinga's Global Small Cap Conference Thursday, May 13, 2021
Check out the full agenda via Benzinga's Events page: https://www.benzinga.com/events/small-cap/global/#agenda * the list below is limited to some of the publicly-traded companies that will be presenting
Check out the full agenda via Benzinga's Events page:  * the list below is limited to some of the publicly-traded companies that will be presenting · 05/13 13:08
Benzinga Pro's Top 6 Stocks To Watch For Thursday, May 13, 2021 (BZ Small Cap Event Edition): UGRO, CANF, MYMD, OBLG, ELYS, GNPX
Today's 5 Stock Ideas (BZ Small Cap Event Edition) Benzinga is hosting another of it's famed Benzinga Global Small Cap Conferences this week!  The festivities kick off Thursday morning just after 9 a.m.
Benzinga · 05/13 12:25
BioMedNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for May Investor Conferences
May 10, 2021 (Investor Brand Network via COMTEX) -- Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing...
Investor Brand Network · 05/10 16:25
Genprex to Participate in Upcoming May Investor Conferences
Genprex will participate in conferences throughout May 2021.
Business Wire · 05/10 12:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNPX. Analyze the recent business situations of Genprex Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNPX stock price target is 6.67 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 85
Institutional Holdings: 8.31M
% Owned: 17.54%
Shares Outstanding: 47.36M
TypeInstitutionsShares
Increased
22
2.08M
New
20
816.93K
Decreased
16
1.66M
Sold Out
4
13.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.27%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Secretary
J. Rodney Varner
Chief Financial Officer
Ryan Confer
Chief Operating Officer/Executive Vice President
Michael Redman
Executive Vice President/General Counsel
Catherine Vaczy
Independent Director
Brent Longnecker
Independent Director
Jose Moreno Toscano
Independent Director
William Wilson
Director
Will Wilson
No Data
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. It is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).

Webull offers kinds of Genprex Inc stock information, including NASDAQ:GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.